Akebia Therapeutics, Inc.
AKBAStock
$1.40−64.74%52W
Market Cap$370.20M
P/E—
Div yield—
Beta0.26
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-13.44%
Price vs S&P 500 (4W)49.54%
VGM Score47.53
Market Capitalization$370.20M
Earnings Surprise History
Q1 26-0.03est. -0.03
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.36
4.36
4.36
4.36
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AKBAAkebia Therapeutics, Inc. | C | C | C | $1.40 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Akebia Therapeutics is a biopharmaceutical company specializing in chronic kidney disease treatments. Its marketed products include Auryxia for serum phosphorus control and iron deficiency anemia in CKD patients in the US, and Vafseo for CKD-related anemia in Japan. The company is advancing HIF-PH inhibitors in preclinical development.